Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 14/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.64 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768189 | 0.89 | KCNH2 (0.80) | CCR5KCNH2GPR119 | |
| SCHEMBL6701416 | 0.83 | CCR5 (0.75) | CCR5KCNH2GPR119 | |
| SCHEMBL13478932 | 0.78 | CHRM4 (0.64) | CHRM2CHRM3 | |
| SCHEMBL5083771 | 0.77 | OPRM1 (0.69) | CCR5KCNH2GPR119CHRM2CHRM3 | |
| SCHEMBL6702550 | 0.77 | CCR5 (0.57) | CCR5KCNH2GPR119 | |
| SCHEMBL6368678 | 0.74 | CCR5 (0.58) | CCR5KCNH2GPR119 | |
| SCHEMBL12207016 | 0.74 | CCR5 (1.00) | CCR5 | |
| SCHEMBL5441160 | 0.74 | CCR5 (0.73) | CCR5KCNH2 | |
| SCHEMBL6091634 | 0.74 | CCR5 (0.84) | CCR5KCNH2 | |
| SCHEMBL14446771 | 0.74 | CCR5 (0.84) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110952-A1 | N-4-piperidinyl compounds as ccr5 modulators | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| EP-1368314-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | AstraZeneca AB (SE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002070479-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110952-A1 | N-4-piperidinyl compounds as ccr5 modulators | CCR5, CCL5, CCR2 | CCR5 1/4885KCNH2 2789/4885GPR119 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.